Psilocybin-Research.com
Research. Clarity. Progress.
Executed search
Sources: bioRxiv
142 matching records are displayed.
Clear search Latest Publications
Most recently published records currently stored in SQLite.
1-20
Last updated: Jul 3, 2026 00:16 UTC
Checking for newly published papers…
Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study
ClinicalTrials.gov · 2026-07-01
Meskalin / Mescaline
Zenodo (CERN European Organization for Nuclear Research) · 2026-06-30
DMT und Ayahuasca / DMT and Ayahuasca
Zenodo (CERN European Organization for Nuclear Research) · 2026-06-30
DMT und Ayahuasca / DMT and Ayahuasca
Zenodo (CERN European Organization for Nuclear Research) · 2026-06-30
Neuroestimulantes naturales: de rituales ancestrales a terapias de vanguardia
Revista CienciaUANL · 2026-06-30
Meskalin / Mescaline
Zenodo (CERN European Organization for Nuclear Research) · 2026-06-30
Usos recreativos, medicinales y etnobotánicos de hongos alucinógenos: una revisión
Multidisciplinary Collaborative Journal · 2026-06-30
Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms
Journal of Drug Issues · 2026-06-30
Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms
ClinicalTrials.gov · 2026-06-30
Psilocybin shows mixed results for patients with treatment-resistant depression
The Brown University Psychopharmacology Update · 2026-06-30
Single-dose psilocybin with CBT more effective than nicotine patch for smoking cessation
The Brown University Psychopharmacology Update · 2026-06-30
Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic review
Journal of Affective Disorders Reports · 2026-06-30
Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders.
Palliative medicine · 2026-06-30
Chemistry/structural biology of psychedelic drugs and their receptor(s).
British journal of pharmacology · 2026-06-30
Record check: Jul 3, 2026 00:16 UTC
Daily cron-ready
142matching papers
3,833psilocybin
553psilocin
388journals
3,974all time
Pyramidal cell types and 5-HT2A receptors are essential for psilocybin’s lasting drug action
Psilocybin is a serotonergic psychedelic with therapeutic potential for treating mental illnesses 1-4. At the cellular level, psychedelics induce structural neural plasticity 5,6, exemplified by the drug-evoked growth and remodeling of dendritic spines in cortical pyramidal cells 7-9. A key question is how these cellular modifications map onto cell type-spec...
Psilocybin Reduces Grooming in the SAPAP3 Knockout Mouse Model of Compulsive Behaviour
Psilocybin is a serotonergic psychedelic compound which shows promise for treating compulsive behaviours. This is particularly pertinent as compulsive disorders require research into new pharmacological treatment options as the current frontline treatments such as selective serotonin reuptake inhibitors, require chronic administration, have significant side ...
The forgotten psychedelic: Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin
As psychedelic-assisted psychotherapy gains momentum, clinical investigation of next-generation psychedelics may lead to novel compounds tailored for specific populations. 2,5-dimethoxy-4-bromophenethylamine (2C-B) is a psychedelic phenethylamine reported to produce less dysphoria and subjective impairment than the psychedelic tryptamine psilocybin. Despite ...
The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice
Recent studies highlight the promising use of psychedelic therapies for psychiatric disorders, including depression. The persisting clinical effects of psychedelics such as psilocybin are commonly attributed to activation of the serotonin 2A receptor (5-HT2AR) based on its role in the acute hallucinatory effects. However, the active metabolite of psilocybin ...
Human brain changes after first psilocybin use
ABSTRACT Psychedelics have robust effects on acute brain function and long-term behavior but whether they also cause enduring functional and anatomical brain changes is unknown. In a placebo-controlled, within-subjects, electroencephalography, and magnetic resonance imaging study in 28 healthy, entirely psychedelic-naive participants, anatomical and function...
Snapshot of 5-HT2A receptor activation in the mouse brain via IP1 detection
The distinct subjective effects that define psychedelics such as LSD, psilocybin or DOI as drug class are causally linked to activation of the serotonin 2A receptor (5-HT2A R). However, some aspects of 5-HT2A R pharmacology remain elusive, such as what molecular drivers differentiate psychedelic from non-psychedelic 5-HT2A R agonists. We developed an ex vivo...
Psilocybin prevents habituation to familiar stimuli and preserves sensitivity to sound following repeated stimulation in mouse primary auditory cortex
Psilocybin, a psychoactive substance derived from fungi, has been utilized historically by diverse cultures for both medicinal and non-medicinal purposes, owing to its ability to elicit profound sensory and cognitive alterations and sustain long-term changes in mood and cognition. Promising results from recent clinical studies have generated a wave of intere...
Distinct classes of antidepressants commonly act to shape pallidal structure and function in mice
Antidepressants including selective serotonin reuptake inhibitors, ketamine, and psilocybin are all effective for treating depression despite their distinct primary mechanisms. We hypothesized that these drugs may share a common mechanism that underlies their therapeutic actions. We treated mice with one of the following: escitalopram, R- / S -/ RS- ketamine...
Premorbid Characteristics of the SAPAP3-Mouse Model of Obsessive-Compulsive Disorder: Behavior, Neuroplasticity, and Psilocybin Treatment
Background SAPAP3-knockout (KO) mice develop excessive self-grooming behavior at 4-6 months of age, serving as a model for obsessive-compulsive disorder (OCD). Given that anxiety often precedes OCD diagnosis in humans, this study investigated whether juvenile SAPAP3-KO mice exhibit anxiety-like behaviors before developing the self-grooming phenotype, and whe...
A virtual clinical trial of psychedelics to treat patients with disorders of consciousness
Disorders of consciousness (DoC), including the unresponsive wakefulness syndrome (UWS) and the minimally conscious state (MCS), have limited treatment options. Recent research suggests that psychedelic drugs, known for their complexity-enhancing properties, could be promising treatments for DoC. This study uses whole-brain computational models to explore th...
Effects of serotonergic psychedelics on synaptogenesis and immediate early genes expression - comparison with ketamine, fluoxetine and lithium
Background: Recent evidence suggests that psychedelics are able to induce rapid and long-lasting antidepressant effects. The generally acknowledged explanation for these traits is the phenomenon of neuroplasticity, although exact underlying molecular mechanisms remain unclear. Aims: This study investigates selected neuroplastic effects of psilocin, lysergic ...
Molecular insights into the modulation of the 5HT 2A receptor by serotonin, psilocin, and the G protein subunit Gqα
SUMMARY The 5HT 2A receptor (5HT 2A R) is a G protein-coupled receptor that drives many neuronal functions and is one of the primary targets for psychedelic drugs, which have recently shown promise in treating mental disorders. Understanding ligand interactions and conformational transitions is essential for developing effective pharmaceuticals, but mechanis...
Psychedelics relax predictive processing in the post-acute period by remodeling cortico-cortical feedback circuits
Serotonergic psychedelics (e.g., psilocybin, LSD) have potential to treat psychiatric disorders, with therapeutic effects lasting days to weeks after a single dose. Prominent theories suggest that psychedelics have a lasting effect on hierarchical brain circuits, reducing top-down influence on information processing to facilitate an unbiased, bottom-up reass...
Striking Long Term Beneficial Effects of Single Dose Psilocybin and Psychedelic Mushroom Extract in the SAPAP3 Rodent Model of OCD-Like Excessive Self-Grooming
Obsessive compulsive disorder (OCD) is a highly prevalent disorder that causes serious disability. Available treatments leave 40% or more of people with OCD significantly symptomatic. There is an urgent need for novel therapeutic approaches. Mice that carry a homozygous deletion of the SAPAP3 gene (SAPAP3 KO) manifest a phenotype of excessive self-grooming, ...
Ketamine-Induced Unresponsiveness Shows a Harmonic Shift from Global to Localised Functional Organisation
Ketamine is classified as a dissociative anaesthetic that, in sub-anaesthetic doses, can produce an altered state of consciousness characterised by dissociative symptoms, visual and auditory hallucinations, and perceptual distortions. Given the anaesthetic-like and psychedelic-like nature of this compound, it is expected to have different effects on brain dy...
Increased 5-HT2A receptor signalling efficacy differentiates serotonergic psychedelics from non-psychedelics
ABSTRACT Background and Purpose Serotonergic psychedelic drugs are under renewed investigation for the potential treatment of several psychiatric disorders. While all serotonergic psychedelics have 5-HT2A receptor activity, the explanation for why some 5-HT2A receptor agonists are not psychedelic is unknown. To address this question, we investigated the 5-HT...
Co-administration of midazolam and psilocybin: Differential effects on subjective quality versus memory of the psychedelic experience
Aspects of the acute experience induced by the serotonergic psychedelic psilocybin predict symptomatic relief in multiple psychiatric disorders and improved well-being in healthy participants, but whether these therapeutic effects are immediate or are based on memories of the experience is unclear. To examine this, we co-administered psilocybin (25 mg) with ...
Psilocybin reduces heroin seeking behavior and modulates inflammatory gene expression in the nucleus accumbens and prefrontal cortex of male rats
Preclinical and human studies indicate psilocybin may reduce perseverant maladaptive behaviors, including nicotine and alcohol seeking. Such studies in the opioid field are lacking, though opioids are involved in more >50% of overdose deaths. Psilocybin is an agonist at the serotonin 2A receptor (5-HT2A R), a well-documented target for modulation of drug see...
Time-resolved coupling between connectome harmonics and subjective experience under the psychedelic DMT
Exploring the intricate relationship between brain's structure and function, and how this affects subjective experience is a fundamental pursuit in neuroscience. Psychedelic substances offer a unique insight into the influences of specific neurotransmitter systems on perception, cognition and consciousness. Specifically, their impact on brain function propag...
Classification of psychedelics and psychoactive drugs based on brain-wide imaging of cellular c-Fos expression
Psilocybin, ketamine, and MDMA are psychoactive compounds that exert behavioral effects with distinguishable but also overlapping features. The growing interest in using these compounds as therapeutics necessitates preclinical assays that can accurately screen psychedelics and related analogs. We posit that a promising approach may be to measure drug action ...